Recent advancements in graphene-based nanomaterials provide the opportunity that compliments the limitations of conventional drug delivery systems (DDSs) through simultaneous targeting of the anticancer drug to the cancer cell by reducing the side effects of other administration routes. Graphene with its extraordinary electronic properties like larger surface area, possibilities of surface modification, can efficiently target the tumor cell. At the same time, nanocarriers have the advantages of immune clearance adulteration of physicochemical properties of anticancer drug. The DDSs can be made by biodegradable nanocarriers such as proteins, peptides, biocompatible polymers, antibodies, polymer-drug conjugates, etc. Graphene-supported DDSs in cancer therapy also supports the co-delivery of therapeutic agents, antioxidants, SiRNA, shRNA, etc. as the co-delivery approach, which provide additive or synergistic therapeutic efficacy and can reduce toxic effects.
Part of the book: Tumor Progression and Metastasis